Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Concomitant Use Of Macugen With Visudyne Appears Safe, Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Concomitant use of Pfizer/Eyetech's Macugen (pegatanib) with Novartis/QLT's Visudyne (verteporfin) does not pose safety concerns, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded Aug. 27.

You may also be interested in...



Miravant's SnET2 Requires Additional Clinical Trial For Macular Degeneration

FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.

Miravant's SnET2 Requires Additional Clinical Trial For Macular Degeneration

FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.

Pfizer/Eyetech's Macugen: Advisory Cmte. Wants Long-Term Follow Up

While the committee finds the existing data were sufficient for approval, members call for long-term follow up to address safety concerns and duration of therapy. The committee also recommends labeling address endophthalmitis.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel